Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily volume of 987,100 shares, the short-interest ratio is presently 2.0 days.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ BCLI remained flat at $0.53 during midday trading on Friday. The stock had a trading volume of 266,201 shares, compared to its average volume of 977,687. The stock has a 50 day moving average of $0.48 and a 200 day moving average of $0.33. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and a 52-week high of $3.34.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. As a group, equities analysts predict that Brainstorm Cell Therapeutics will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They issued a “sell” rating on the stock.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.